ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022
First report of auxiliary liver transplantation for severe cholangiopathy after SARS-CoV-2 respiratory infection.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- New onset of severe and long-term hepatobiliary diseases post-COVID-19 infection: a systematic review.BMC infectious diseases · 2026Pooled it
- A single-nucleus and spatial transcriptomic atlas of the COVID-19 liver reveals topological, functional, and regenerative organ disruption in patients.Genome biology · 2025Article
- Solid Organ Transplants Caused by COVID-19 Infection and the Outcome of Transplantation Post-COVID-19: A Systematic Review.Biomedicines · 2025Review
- Post-COVID-19 cholangiopathy: Current understanding and management options.World journal of gastrointestinal surgery · 2023Review
- COVID-19 related biliary injury: A review of recent literature.World journal of gastroenterology · 2023Review
- Post-COVID-19 Cholangiopathy: A Recent Indication for Liver Transplantation.Journal of clinical medicine research · 2023Article
- COVID-19 and hepatic injury: cellular and molecular mechanisms in diverse liver cells.World journal of gastroenterology · 2023Review
- Secondary Sclerosing Cholangitis After SARS-CoV2: ICU Ketamine Use or Virus-Specific Biliary Tropism and Injury in the Context of Biliary Ischemia in Critically Ill Patients?Hepatic medicine : evidence and research · 2023Article
- COVID-Associated Cast-Forming Cholangiopathy: A Commentary on Disease Mechanism, Treatment, and Prognosis.Hepatic medicine : evidence and research · 2023Article
- COVID-19-Associated Liver Injury.Hepatic medicine : evidence and research · 2023Review
- Challenges in liver transplantation in the context of a major pandemic.World journal of transplantation · 2022Review
- Impact of the COVID-19 Pandemic on Patients with End-Stage Liver Disease: One Virus-A Plethora of Consequences.Journal of clinical and experimental hepatologyArticle
- Post-COVID-19 Cholangiopathy: A Systematic Review.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-coronavirus disease 2019 (COVID-19) cholangiopathy (PCC) is a new entity observed in patients recovering from severe COVID-19 pneumonia. Most patients recover with cholestasis improving over a period of time. In some patients, cholestasis is severe and persists or progresses to liver failure necessitating liver transplant. We present a previously healthy 50-year-old man who developed PCC with peak total bilirubin of 42.4 mg/dl and did not improve with medical management. He underwent living donor auxiliary right lobe liver transplantation. He recovered well after transplant and remains asymptomatic at 6 months follow-up with good graft function and recovering function in native liver remnant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.